Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.

• Hlavní autoři: Aurélie Chauffour (Autor), Jérôme Robert (Autor), Nicolas Veziris (Autor), Alexandra Aubry (Autor), Kevin Pethe (Autor), Vincent Jarlier (Autor)
• Médium: Kniha
• Vydáno: Public Library of Science (PLoS), 2020-08-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimic...